Keyword: Seattle Genetics

Seattle Genetics names Keytruda developer as CMO and Aravive CEO Stephen Eck leaves to join Immatics.

Seattle Genetics appointed Roger Dansey as CMO, who led Merck’s late-stage oncology work, including developing Keytruda in multiple tumor types.

Immunomedics is drawing a deeper line under its woes with a new head of research from AstraZeneca.

Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.

After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.

News that the Trump administration is axing the Obama-era Deferred Action for Childhood Arrivals program has been met with dismay by biotech leaders.

Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.

Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.

Scott Gottlieb was confirmed to lead FDA, neuroscientist Thomas Insel left Verily, Immunomedics' CEO and CSO stepped down.

Seattle Genetics terminated a major drug tie-up with Immunomedics after intense legal battles, as Immunomedics axed CEO Cynthia Sullivan.